# ExCellThera

Source: https://onco.cc/companies/excellthera/  
OnCo record `excellthera` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ExCellThera is a Montreal cell-therapy company that uses the small molecule UM171 to multiply blood stem cells from cord blood, making transplants possible for patients who would otherwise lack a donor.

## Summary

ExCellThera was spun out of Université de Montréal around UM171, a molecule discovered in Guy Sauvageau's laboratory that expands haematopoietic stem cells in culture. Its product, dorocubicel (ECT-001, UM171-expanded cord blood), lets a small cord blood unit be grown into a graft for adults with high-risk blood cancers who lack a matched donor. Phase 2 trials in acute leukaemia and myelodysplastic syndromes have reported low rates of chronic graft-versus-host disease and relapse.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: ExCellThera Inc.
- Tags: drug-maker
- HQ: Montreal
- Type: cell-therapy
- Website: https://www.excellthera.com/

## Sources

- Official website: https://www.excellthera.com/

## Connected records

- drugs: [Dorocubicel (UM171-expanded cord blood)](https://onco.cc/drugs/dorocubicel/)

---
JSON: https://onco.cc/api/v1/entities/excellthera.json